Inclusion Criteria:

- Histologically confirmed diagnosis of recurrent B cell non-Hodgkin's lymphoma or
diagnosis of recurrent chronic lymphocytic leukemia

- Patient has received at least one prior treatment with standard chemotherapy and at
least one prior treatment with rituximab (negative HAHA test required if received
prior humanized antibody treatment)

- Patient has not received anti-cancer therapy within 28 days of treatment unless
disease progression has been demonstrated and toxicities from prior therapy have
resolved

- Available tumor tissue (lymph node/mass, blood or bone marrow) for correlative
analyses (paraffin or frozen, recent or archived)

- Measurable disease as defined by a tumor mass > 1.5 cm in one dimension or WBC >
5,000 (CLL patients)

- Age > 18 years

- Patient has KPS > 50%

- Absolute granulocyte count > 1000 cells/mm3

- Platelet count > 50,000 cells/mm3

- Creatinine < 2.0 x ULN

- Total bilirubin < 2.0 x ULN

- Patient agrees to use birth control if of reproductive potential

- Patient has signed IRB-approved informed consent

Exclusion Criteria:

- Known central nervous system (CNS) involvement by lymphoma

- Known HIV disease

- Patient is pregnant or nursing

- Patient is receiving other investigational drugs

- Known serum human anti-human antibodies (HAHA)

- Estimated life expectancy of < 3 months